ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0407

The SOS project: to Switch Or to Swap After Adalimumab failure for the management of childhood non-infectious uveitis in an international cohort
Abstract Number: 1717

The Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) Predicts Mortality In Systemic Lupus Erythematosus (SLE) Patients: Data From The Almenara Lupus Cohort
Abstract Number: 0605

The Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) Predicts Worsening Self-Efficacy in the Patients from the Almenara Lupus Cohort
Abstract Number: 0934

The Use Of Preclinical Models To Understand Drivers Of Lupus Pathogenesis
Abstract Number: 0620

The usefulness of neutrophil-to-lymphocyte ratio as a biomarker to predict lupus flares in patients under remission
Abstract Number: 0793

The weight of the past: how trauma and resilience shape medication adherence in SLE
Abstract Number: 1977

The Westergren Sedimentation Rate: To Be or Not to Be! The Westergren Sedimentation Rate is being “Killed” but has not “Died”.
Abstract Number: 0877

Therapeutic Approach in Patients with Arthralgia at Risk of Progression to Psoriatic Arthritis.
Abstract Number: 0618

Therapeutic landscape of systemic lupus erythematosus pure membranous nephropathy: a nationwide population-based study
Abstract Number: 0100

Therapeutic Modulation of NAD+ Metabolism in Inflammatory Rheumatic Disorders by TNFi and NAD+ Precursors
Abstract Number: 0952

Therapeutic Potential of PaPE-1 in Reducing TLR7-Mediated Inflammation in a Murine Model of Lupus
Abstract Number: 2137

Therapeutic Strategies in Newly Diagnosed Still’s Disease: Real-Life Clinicians’ Choices from the METAPHOR Project Worldwide Survey
Abstract Number: 1886

Thirty Percent of Older Adults with Rheumatic Disease Receive High-Risk Medication
Abstract Number: 0119

Thrombin Generation Assays Inform Hypercoagulability Mediated by Antiphospholipid Antibodies in Children with Systemic Lupus Erythematosus
Abstract Number: 1501

Thrombocytopenia in SLE: A Hidden Prognostic Marker of Increased Mortality and Adverse Outcomes – Results from Real World Data

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].